<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03467373</url>
  </required_header>
  <id_info>
    <org_study_id>NP40126</org_study_id>
    <secondary_id>2017-003648-18</secondary_id>
    <nct_id>NCT03467373</nct_id>
  </id_info>
  <brief_title>A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Chemotherapy in Participants With Non-Hodgkin Lymphomas</brief_title>
  <official_title>A Phase 1B Study Evaluating RO7082859 in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Relapsed Refractory Follicular Lymphoma (R/R FL) or in Participants With Untreated Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1B, multi-center, dose-finding study of RO7082859 administered in combination
      with obinutuzumab (Gazyva; [G]), rituximab (R) and standard doses of CHOP (G/R-CHOP or
      R-CHOP) in participants with Grades 1-3a r/r FL and untreated diffuse large B-cell lymphoma
      (DLBCL). Evaluating the safety, preliminary activity, pharmacokinetic (PK), and
      pharmacodynamic effects of this combination will be the main objectives of this study. The
      study is divided in two parts:

        -  Part I: Dose finding in participants with r/r FL

        -  Part II: Dose expansion in which the maximum tolerated dose (MTD) (or optimal biologic
           dose [OBD]) determined in Part I will be further assessed in participants with r/r FL
           and those with untreated DLBCL (&gt;60 years old with an age-adjusted International
           Prognostic Index [IPI]) of 2-3), and the impact of using G in place of R in Cycle 1 on
           safety and tolerability will be assessed via a randomized, unblinded, two-arm design in
           participants with untreated DLBCL.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part I: Percentage of Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 29 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part I and II: Percentage of Participants with Adverse Events</measure>
    <time_frame>Up to 29 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part II: Percentage of Participants with a Complete Response (CR) as Assessed by the Investigator using Modified Lugano 2014 Criteria</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Percentage of Participants with Overall Response (Partial Response [PR] or Complete Response [CR])</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Percentage of Participants with PR, CR or SD (Disease Control Rate [DCR])</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Duration of Response (DOR)</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Area Under the Serum Concentration Versus Time Curve (AUC) of RO7082859</measure>
    <time_frame>Cycle 1 Day 1 up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Time to Maximum Serum Concentration (tmax) of RO7082859</measure>
    <time_frame>Cycle 1 Day 1 up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Par II: Maximum Serum Concentration (Cmax) of RO7082859</measure>
    <time_frame>Cycle 1 Day 1 up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Minimum Serum Concentration (Cmin) of RO7082859</measure>
    <time_frame>Cycle 1 Day 1 up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in T-cell Activation Markers</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Area Under the Serum Concentration Versus Time Curve (AUC) of Rituxiamb</measure>
    <time_frame>Cycle 1 Day 1 up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Time to Maximum Serum Concentration (tmax) of Rituximab</measure>
    <time_frame>Cycle 1 Day 1 up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Par II: Maximum Serum Concentration (Cmax) of Rituximab</measure>
    <time_frame>Cycle 1 Day 1 up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Minimum Serum Concentration (Cmin) of Rituximab</measure>
    <time_frame>Cycle 1 Day 1 up to 29 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Follicular Lymphoma</condition>
  <condition>B-Cell Lymphoma</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose Escalation r/r FL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose finding in participants with r/r FL: the study will explore different doses of RO7082859 in the induction period, starting at a dose of 70 mcg administered in combination with standard of care doses of G/R CHOP and R-CHOP on an every 3 weeks (Q3W) schedule. Participants with r/r FL will receive 6 cycles (Cycles 1-6) of induction treatment (G/R-CHOP). RO7082859 will be administered in Cycles 2-6 on Day 8. Participants who achieve a complete response (CR), partial response (PR), or stable disease (SD) at the end of induction (EOInd) will receive post-induction treatment (referred to as maintenance) with RO7082859 alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Dose Expansion r/r FL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with r/r FL will be assigned to an expansion cohort to further explore RO7082859 at the MTD/OBD determined in Part I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: DLBCL G-CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with untreated DLBCL will receive G-CHOP in Cycle 1, followed by R-CHOP + RO7082859 in cycles 2-8. The starting dose of RO7082859 for each arm may be one or more levels below the MTD/OBD determined in Part I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: DLBCL R-CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with untreated DLBCL will receive R-CHOP in Cycle 1, followed by R-CHOP + RO7082859 in cycles 2-8. The starting dose of RO7082859 for each arm may be one or more levels below the MTD/OBD determined in Part I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7082859</intervention_name>
    <description>RO7082859 will be administered intravenously (IV) at a dose and as per the schedule specified in the respective arms.</description>
    <arm_group_label>Part 1: Dose Escalation r/r FL</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion r/r FL</arm_group_label>
    <arm_group_label>Part 2: DLBCL G-CHOP</arm_group_label>
    <arm_group_label>Part 2: DLBCL R-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab (G)</intervention_name>
    <description>Obinutuzumab 1000 mg single dose IV infusion on Day 1 of Cycle 1 only</description>
    <arm_group_label>Part 1: Dose Escalation r/r FL</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion r/r FL</arm_group_label>
    <arm_group_label>Part 2: DLBCL G-CHOP</arm_group_label>
    <other_name>Gazyva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab (R)</intervention_name>
    <description>Rituximab will be administered as an IV infusion at a dose of 375 mg/m^2 on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Part 1: Dose Escalation r/r FL</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion r/r FL</arm_group_label>
    <arm_group_label>Part 2: DLBCL R-CHOP</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab will be administered as an IV infusion as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents. Tocilizumab will be given as rescue medication.</description>
    <arm_group_label>Part 1: Dose Escalation r/r FL</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion r/r FL</arm_group_label>
    <arm_group_label>Part 2: DLBCL G-CHOP</arm_group_label>
    <arm_group_label>Part 2: DLBCL R-CHOP</arm_group_label>
    <other_name>Actemra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 750 mg/m^2 administered IV on Day 1 of each 21-day cycle</description>
    <arm_group_label>Part 1: Dose Escalation r/r FL</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion r/r FL</arm_group_label>
    <arm_group_label>Part 2: DLBCL G-CHOP</arm_group_label>
    <arm_group_label>Part 2: DLBCL R-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 50 mg/m^2 administered IV on Day 1 of each 21-day cycle</description>
    <arm_group_label>Part 1: Dose Escalation r/r FL</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion r/r FL</arm_group_label>
    <arm_group_label>Part 2: DLBCL G-CHOP</arm_group_label>
    <arm_group_label>Part 2: DLBCL R-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine 1.4 mg/m^2 administered by IV push on Day 1 of each 21-day cycle with a recommended cap of 2 mg</description>
    <arm_group_label>Part 1: Dose Escalation r/r FL</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion r/r FL</arm_group_label>
    <arm_group_label>Part 2: DLBCL G-CHOP</arm_group_label>
    <arm_group_label>Part 2: DLBCL R-CHOP</arm_group_label>
    <other_name>Oncovin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 100 mg/day orally on Days 1-5 (prednisone on Day 1 may be administered IV, with the remaining doses on Days 2-5 to be administered orally) of each 21-day cycle</description>
    <arm_group_label>Part 1: Dose Escalation r/r FL</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion r/r FL</arm_group_label>
    <arm_group_label>Part 2: DLBCL G-CHOP</arm_group_label>
    <arm_group_label>Part 2: DLBCL R-CHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 60 years for patients with untreated DLBCL

          -  A history or status of: 1) histologically-confirmed r/r FL and previously untreated
             DLBCL that are expected to express CD20; 2) for participants diagnosed with DLBCL,
             they must be previously untreated; 3) for participants with r/r FL, they must display
             relapse after or failure to respond to at least one prior treatment regimen

          -  Able to provide a pretreatment biopsy between the last dose of last prior therapy and
             initiation of study medication at Cycle 1/Day 1

          -  Participants must have at least one measurable target lesion (&gt; or = 1.5 cm) in its
             largest dimension by computed tomography scan

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 for
             participants with r/r FL; ECOG performance status 0-3 for participants with untreated
             DLBCL

          -  Life expectancy (in the opinion of the Investigator) of 18 weeks

          -  Adverse events (AEs) from prior anti-cancer therapy must have resolved to Grade &lt; or =
             1

          -  Adequate liver function

          -  Adequate hematological function

          -  Adequate renal function

          -  Negative serologic or polymerase chain reaction (PCR) test results for acute or
             chronic hepatitis B virus (HBV) infection

          -  Negative test results for hepatitis C virus (HCV) and human immunodeficiency virus
             (HIV)

        Exclusion Criteria:

          -  Inability to comply with protocol mandated hospitalization and restrictions

          -  Participants with known active infection, or reactivation of a latent infection within
             4 weeks of dosing

          -  Prior treatment with systemic immunotherapeutic agents, including, but not limited to,
             radioimmuno-conjugates, antibody-drug conjugates, immune/cytokines, and monoclonal
             antibodies (e.g., anti-CTLA4, anti-PD1, and anti-PDL1) within 4 weeks or five
             half-lives of the drug, whichever is shorter, before G- or R-CHOP infusion on Cycle
             1/Day 1

          -  History of treatment-emergent immune-related AEs associated with prior
             immunotherapeutic agents

          -  Contraindication to any of the individual components of the chemotherapy

          -  Documented refractoriness to an obinutuzumab-monotherapy regimen

          -  Treatment with standard radiotherapy, any chemotherapeutic agent, or treatment with
             any other investigational anti-cancer agent within 4 weeks prior to study treatment at
             Cycle 1/Day 1 infusion

          -  Prior solid organ transplantation

          -  Prior allogeneic stem cell transplantation

          -  Autologous stem cell transplantation within 100 days prior to Cycle 1/Day 1

          -  History of autoimmune disease

          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
             antibody therapy

          -  A history of confirmed progressive multifocal leukoencephalopathy

          -  Current or past history of central nervous system (CNS) lymphoma

          -  Ongoing corticosteroid use &gt; 30 mg/day of prednisone or equivalent

          -  Participants with r/r FL must not have received prior therapy with an anthracycline

          -  Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or
             neurodegenerative disease

          -  Evidence of significant, uncontrolled concomitant diseases that could affect
             compliance with the protocol or interpretation of results, including diabetes
             mellitus, history of relevant pulmonary disorders (bronchospasm, obstructive pulmonary
             disease), and known autoimmune diseases

          -  Major surgery or significant traumatic injury &lt; 28 days prior to the study treatment
             infusion at Cycle 1/Day 1 (excluding biopsies) or anticipation of the need for major
             surgery during study treatment

          -  Participants with another invasive malignancy that could affect compliance with the
             protocol or interpretation of results

          -  Significant cardiovascular disease

          -  Left ventricular ejection fraction &lt; 50%

          -  Administration of a live, attenuated vaccine within 4 weeks before study treatment
             infusion on Cycle 1 Day 1 or anticipation that such a live, attenuated vaccine will be
             required during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Reference Study ID: NP40126 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peter Maccallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute; Clinical Trials</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital, Medical Oncology &amp; Haematology</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo.</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg; Studienzentrale Hämatologie/Onkologie</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron; Servicio de Hematologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The HOPE Clinical Trials Unit</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust; NIHR UCLH Clinical Research Facility</name>
      <address>
        <city>London</city>
        <zip>W1T 7HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

